Effect Of Brain Metastases On Survival And Systemic Treatment Of Egfr/Alk-Driven Non-Small Cell Lung Cancer (Nsclc).

e20527Background: Survival with EGFR/ALK+ve NSCLC can be prolonged with tyrosine kinase inhibitors (TKIs), but brain metastases (mets) are common. TKIs may control brain mets poorly, and radiation may have neurocognitive toxicity. Deteriorating performance status (PS) due to brain mets may affect the number of lines of treatment. We aimed to evaluate the impact of brain mets on lines of systemic therapy and overall survival (OS). Methods: This retrospective analysis included patients with EGFR/ALK+ve NSCLC treated at Princess Margaret Cancer Centre from 1998-2015. 2 groups were analyzed: those with brain mets at diagnosis of stage IV disease or on 1st line therapy, and those without brain mets. OS was calculated from date of metastatic disease using Kaplan-Meier method, and differences between groups were tested with the log-rank test. Results: 291 patients were included: 141 with and 150 without brain mets. Summary results are shown in the Table. 106/141 had brain mets at diagnosis of stage IV NSCLC. The...